1. Bacillus Calmette-Guerin and interleukin-2 for treatment of superficial bladder cancer.
- Author
-
Cockett AT, Davis RS, Cos LR, and Wheeless LL Jr
- Subjects
- BCG Vaccine therapeutic use, Carcinoma in Situ pathology, Carcinoma in Situ therapy, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell therapy, Humans, Interleukin-2 therapeutic use, Male, Urinary Bladder Neoplasms pathology, BCG Vaccine administration & dosage, Interleukin-2 administration & dosage, Urinary Bladder Neoplasms therapy
- Abstract
A total of 22 patients with bladder cancer received bacillus Calmette-Guerin (BCG) and interleukin-2. Significant bladder tumor remissions were noted in 15 of 17 patients (88%). Of 5 patients with carcinoma in situ 1 was noncompliant and he died of carcinoma in situ. The other 4 patients are in remission. BCG alone was instilled in 22 additional patients with superficial bladder cancer. The remission rates were encouraging. Of the 22 patients 13 (59%) had remission of the bladder tumor. A half dose of BCG (60 mg.) is adequate when given weekly for 6 weeks. Maintenance therapy is important as noted in both of our clinical arms. BCG and interleukin-2 therapy results in a higher remission rate.
- Published
- 1991
- Full Text
- View/download PDF